Cargando…

Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange

Ras mutations are the oncogenic drivers of many human cancers and yet there are still no approved Ras-targeted cancer therapies. Inhibition of Ras nucleotide exchange is a promising new approach but better understanding of this mechanism of action is needed. Here we describe an antibody mimetic, DAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillard, Sandrine, Kolasinska-Zwierz, Paulina, Debreczeni, Judit, Breed, Jason, Zhang, Jing, Bery, Nicolas, Marwood, Rose, Tart, Jon, Overman, Ross, Stocki, Pawel, Mistry, Bina, Phillips, Christopher, Rabbitts, Terence, Jackson, Ronald, Minter, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519984/
https://www.ncbi.nlm.nih.gov/pubmed/28706291
http://dx.doi.org/10.1038/ncomms16111
Descripción
Sumario:Ras mutations are the oncogenic drivers of many human cancers and yet there are still no approved Ras-targeted cancer therapies. Inhibition of Ras nucleotide exchange is a promising new approach but better understanding of this mechanism of action is needed. Here we describe an antibody mimetic, DARPin K27, which inhibits nucleotide exchange of Ras. K27 binds preferentially to the inactive Ras GDP form with a K(d) of 4 nM and structural studies support its selectivity for inactive Ras. Intracellular expression of K27 significantly reduces the amount of active Ras, inhibits downstream signalling, in particular the levels of phosphorylated ERK, and slows the growth in soft agar of HCT116 cells. K27 is a potent, non-covalent inhibitor of nucleotide exchange, showing consistent effects across different isoforms of Ras, including wild-type and oncogenic mutant forms.